Abstract Details

Title A Retrospective Cohort Study of Recent Large Multiple Commercial Payer Databases to Elucidate Migraine-specific Costs of Care by specific Treatment Groups

Topic Headache

Presentation(s) P1 - Poster Session 1 (8:00 AM-9:00 AM)

Poster/Presentation
Number 12-006

Objective This Retrospective observational cohort analysis of migraine patients in the US aimed to evaluate the current medication costs associated with the treatment of Migraine, stratified by distinct treatment groups.

Background Migraine, affecting 14% of the population, is a significant healthcare burden. While generic treatments are affordable, newer anti-CGRP (calcitonin gene-related peptide) medications may raise costs. This study examines current medication expenses within our large US Migraine patient group, stratifying costs by treatment groups.

Design/Methods Migraine cases were categorized as Chronic or Other Migraine using ICD-10 codes. Treatment groups were determined hierarchically based on baseline treatments: anti-CGRP, non-specific preventive or acute treatment, or no treatment. Data from Health Verity, comprising 187,780 cases, covered the 12-month periods before and after the index date (8/1/2018 - 7/31/2021).

Results Anti-CGRP treatment group had the highest total pharmacy and medical cost among all treatment groups. During the follow-up period, within Chronic Migraine the Migraine-Specific total pharmacy cost for the anti-CGRP group was $5,555 PPPY (per patient per year) and is 6.5 times higher compared to the next treatment group - Preventative Non-Specific - $857 PPPY. All-Cause Total Pharmacy Cost for anti-CGRP group was $9,331 PPPY and is 2.4 times higher compared to the next treatment group - Preventative Non-Specific - $3,882. The same trend is observed in the Other Migraine group.

Conclusions

This analysis of recent medication costs within Migraine treatment groups reveals the dominant impact of anti-CGRP medications. The anti-CGRP group consistently exhibits markedly higher Total Pharmacy costs for both all-cause and migraine-specific expenses in Chronic and Other Migraine categories. This underscores the profound financial influence of anti-CGRP treatments on overall healthcare costs within these groups.

Authors/Disclosures
Olya Besedina (Click Therapeutics Inc.) PRESENTER	Miss Besedina has nothing to disclose.
Mariya Petrova (Click Therapeutics)	Mariya Petrova has received personal compensation for serving as an employee of Click Therapeutics. Mariya Petrova has received research support from NIH.
Brendan Hare	No disclosure on file
Alankar Gupta, MD (Click Therapeutics)	Dr. Gupta has nothing to disclose.
Shaheen E. Lakhan, MD, PhD, MEd, FAAN	Dr. Lakhan has received personal compensation for serving as an employee of Zogenix, Fern Health, Thriveworks, The Learning Corp, TriNet, Click Therapeutics. Dr. Lakhan has received personal compensation in the range of $1,000,000+ for serving as a Consultant for Shaheen Lakhan, MD, PhD, LLC. Dr. Lakhan has received personal compensation in the range of $100,000-$499,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Neurocrine, Fern Health, Lin Health. Dr. Lakhan has received personal compensation in the range of $500,000-$999,999 for serving as an officer or member of the Board of Directors for Click Therapeutics, SpineThera. Dr. Lakhan has stock in Zogenix, NeuroSport, Click Therapeutics, SpineThera.

��ɫ��

��ɫ��